Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Form 6-K Ascendis Pharma A/S For: Sep 16
September 16, 2024 7:32 AM EDT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
... MoreForm 6-K Ascendis Pharma A/S For: Sep 16
September 16, 2024 7:29 AM EDT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
... MoreForm 6-K Ascendis Pharma A/S For: Sep 11
September 12, 2024 6:01 AM EDT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION... More
